PharmAla Biotech Holdings, Inc. (TSE:MDMA) has released an update.
PharmAla Biotech Holdings Inc. has unveiled its exclusive Prescribers Portal, designed to educate medical professionals on MDMA therapy, specifically for PTSD treatment, amidst a growing acceptance of psychedelic-based treatments. The portal offers resources and tools for practitioners, with upcoming accredited education modules for Canadian and Australian physicians. Additionally, the company is planning a webinar on May 15th to showcase the platform’s features to registered medical professionals.
For further insights into TSE:MDMA stock, check out TipRanks’ Stock Analysis page.
